On Nov 13, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $160 to $175.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $135 to $160.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $145 to $175.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $120 to $160.
CCORF analyst Kyle Mikson CFA maintains with a buy rating, and adjusts the target price from $150 to $165.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
Natera has delivered another robust quarter, according to an analyst. With a strong performance across volume, selling price, margin, and cash management, the company is perceived as operating effectively, with potential for further enhancement leading into 2025. The consensus is that Natera stands out as one of the most distinguished entities in the diagnostics sector.
Natera's Q3 results significantly exceeded expectations, continuing to enhance its core fundamentals. The company is strategically reinvesting its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
The company recorded another robust quarter with its sales, margins, and cash flow all surpassing expectations.
Natera's third quarter revenue and gross margins exceeded estimates, showing robust performance. The company's progress is widespread, highlighted by a 60% annual increase in Signatera clinical volume growth and significant gains within women's health accounts.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月13日，多家华尔街大行更新了$Natera (NTRA.US)$的评级，目标价介于160美元至175美元。
摩根大通分析师Rachel Vatnsdal维持买入评级，并将目标价从135美元上调至160美元。
TD Cowen分析师Daniel Brennan维持买入评级，并将目标价从145美元上调至175美元。
贝雅分析师Catherine Ramsey Schulte维持买入评级，并将目标价从120美元上调至160美元。
CCORF分析师Kyle Mikson CFA维持买入评级，并将目标价从150美元上调至165美元。
此外，综合报道，$Natera (NTRA.US)$近期主要分析师观点如下：
据分析师称，natera已经交付了另一个强劲的季度。公司在成交量、销售价格、利润率和现金管理等方面表现强劲，被认为能够有效运营，并有潜力在2025年进一步提升。共识是，natera在诊断板块中脱颖而出，被视为最杰出的实体之一。
natera的第三季度业绩显著超出预期，继续增强其核心基本面。该公司正在战略性地将经营现金流重新投入业务中，从而加强在销售、营销、医疗事务和法律方面的地位。
该公司再次录得强劲的季度，其销售额、利润率和现金流均超出预期。
natera的第三季度营业收入和毛利率超出了预期，表现强劲。该公司的进展广泛，Signatera临床成交量增长年增幅达60%，在妇女健康账户中取得了显著收益。
以下为今日4位分析师对$Natera (NTRA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
